Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This clinically oriented book is the first to be devoted wholly to the diagnosis and treatment of vitreo-macular interface disease, characterized by a combination of vitreo-macular adhesion (VMA) and vitreo-macular traction (VMT) that is implicated in a variety of disorders. World-renowned experts in the field discuss epidemiologic, anatomic, and physiologic aspects, document the findings obtained with newer imaging techniques, such as spectral domain optical coherence tomography, describe the treatment options, and report on the results of preclinical and clinical trials, including some previously unpublished findings. This book will prove invaluable for ophthalmologists as we advance toward a future in which treatments of diseases such as age-related macular degeneration and diabetic retinopathy will likely require adjunctive therapy to tackle VMA/VMT concurrently.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This clinically oriented book is the first to be devoted wholly to the diagnosis and treatment of vitreo-macular interface disease, characterized by a combination of vitreo-macular adhesion (VMA) and vitreo-macular traction (VMT) that is implicated in a variety of disorders. World-renowned experts in the field discuss epidemiologic, anatomic, and physiologic aspects, document the findings obtained with newer imaging techniques, such as spectral domain optical coherence tomography, describe the treatment options, and report on the results of preclinical and clinical trials, including some previously unpublished findings. This book will prove invaluable for ophthalmologists as we advance toward a future in which treatments of diseases such as age-related macular degeneration and diabetic retinopathy will likely require adjunctive therapy to tackle VMA/VMT concurrently.